88594-08-5|CD-349|3-(2-(nitrooxy)propyl) 5-(3-(nitrooxy)propyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate|-范德生物科技公司

CD-349

NMR下载 COA and HPLC MSDS下载
names：
3-(2-(nitrooxy)propyl) 5-(3-(nitrooxy)propyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
CAS号：
88594-08-5
MDL Number：
MF(分子式)： C21H24N4O12 MW(分子量)： 524.439
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	CD-349
英文别名	CD-349; CD 349; CD349.
CAS号	88594-08-5
Inchi	InChI=1S/C21H24N4O12/c1-12(37-25(32)33)11-35-21(27)18-14(3)22-13(2)17(20(26)34-8-5-9-36-24(30)31)19(18)15-6-4-7-16(10-15)23(28)29/h4,6-7,10,12,19,22H,5,8-9,11H2,1-3H3
InchiKey	QSTCLWROWBZZLA-UHFFFAOYSA-N
分子式 Formula	C21H24N4O12
分子量 Molecular Weight	524.439
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	CD-349(CAS:88594-08-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	CD-349 is a calcium channel antagonist potentially for the treatment of angina pectoris and hypertension. CD-349 inhibited the noradrenaline (NA)-induced contraction of aortas in Ca2(+)-free medium. The blocking effect of CD349 on neuronal Ca2+ influx, in combination with a cerebral vasodilatory action, may contribute to a favorable effect on ischemic brain damage.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Miyata N, Yamaura H, Tsuchida K, Otomo S, Miyajima E. Role of cyclic GMP in inhibitory effects of CD-349 in isolated blood vessels. Gen Pharmacol. 1994 Mar;25(2):267-73. PubMed PMID: 8026725.

[2]Ogawa N, Mizuno K, Fukushima K, Suwa T, Satoh T. Metabolic fate of a new dihydropyridine calcium antagonist, CD-349, in rat and dog. Xenobiotica. 1993 Jul;23(7):747-59. PubMed PMID: 8237057.

[3] Ogawa T, Nakazato A, Tsuchida K, Hatayama K. Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5-positions. Chem Pharm Bull (Tokyo). 1993 Jun;41(6):1049-54. PubMed PMID: 8370105.

[4] Satoh H, Tsuchida K. Comparison of a calcium antagonist, CD-349, with nifedipine, diltiazem, and verapamil in rabbit spontaneously beating sinoatrial node cells. J Cardiovasc Pharmacol. 1993 May;21(5):685-92. PubMed PMID: 7685436.

[5] Miyata N, Yamaura H, Tsuchida K, Otomo S. Effects of CD-349 and 8-BrcGMP on isoproterenol-induced relaxation in rabbit aorta precontracted with endothelin-1. Am J Physiol. 1992 Oct;263(4 Pt 2):H1113-8. PubMed PMID: 1329561.

6: Takahashi T, Hisa H, Satoh S. Serotonin-induced vasoconstriction in dog kidney. J Cardiovasc Pharmacol. 1992;20(5):779-84. PubMed PMID: 1280741.7: Tsuchida K, Kaneko K, Aihara H. Electrophysiological effects of CD-349, a dihydropyridine-type calcium antagonist, on goat cardiac Purkinje fibers. J Cardiovasc Pharmacol. 1991 Nov;18(5):769-76. PubMed PMID: 1723775.8: Oyama Y, Nakaye T, Akaike N, Tsuchida K. Effect of CD349, a new dihydropyridine derivative Ca2+ antagonist, on the voltage-dependent Ca2+ currents in isolated mammalian brain neurons. Arch Int Pharmacodyn Ther. 1991 Sep-Oct;31

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开